Loading...
Loading...
URGN| Name | Value |
|---|---|
| Revenues | 20.9M |
| Cost of Revenue | 2.4M |
| Gross Profit | 18.5M |
| Operating Expense | 32.0M |
| Operating I/L | -13.5M |
| Other Income/Expense | -8.4M |
| Interest Income | 0.8M |
| Pretax | -21.9M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | -21.9M |
UroGen Pharma Ltd. is a biotechnology company specializing in the development and commercialization of innovative solutions for specialty cancers and urothelial diseases. The company's primary focus is on advancing its lead product candidate, UGN-102, through Phase III clinical trials for the treatment of various forms of non-muscle invasive urothelial cancer. Additionally, UroGen Pharma offers RTGel, a hydrogel technology designed to enhance the therapeutic profiles of existing drugs, and has a strategic research collaboration with MD Anderson to advance investigational treatments for high-grade bladder cancer.
